Wong 1994.

Methods	Setting: UK, hospital outpatient clinic Randomisation: yes, method not stated Allocation concealment: unclear Design: parallel Intervention period: 2 weeks Masking: double blind Excluded: not stated Withdrawals: stated Baseline characteristics: comparable Jadad score=3
Participants	19 adults Mean age: budesonide 30 years, placebo 31years Inclusion criteria: Clinical diagnosis of asthma FEV1 (% predicted) >65 15% or greater increase in FEV1 after inhaled beta2 agonist Histamine BHR (PC20 FEV1) < 4 micromols Positive skin prick test to cat fur, grass pollen or house dust mite Exclusion criteria: Treatment other than beta2 agonist Smokers within last 5 years
Interventions	1. BUD 400mcg 2xdaily (800mcg/d) 2. Placebo 2xdaily 3. BUD 400 mcg2xdaily (800 mcg/d)+ terbutaline 1000 mcg/d 4. Terbutaline 1000 mcg/d Delivery device: Turbohaler DPI
Outcomes	Change in FEV1 compared to baseline Change in morning PEFR compared to baseline Change in evening PEFR compared to baseline Change in allergen BHR (PC20 FEV1) compared to baseline Change in histamine BHR (PD20 FEV1) compared to baseline Change in daytime asthma symptom score compared to baseline Change in daily beta2 agonist use compared to baseline Withdrawal due to asthma exacerbation Incidence of oropharyngeal side effects
Notes	No reply from author to clarify details of randomisation method. 2 intervention groups received either BUD+terbutaline or terbutaline alone. The results for these groups have not been considered in this meta‐analysis. Allergen challenge, diary card PEFR, symptom scores and beta2 agonist use were reported using medians and ranges and analysed using non‐parametric methods. The data has therefore not been used in the meta‐analysis. Histamine challenge data not log transformed prior to analysis.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear